Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas

Malignant gliomas account for approximately 60% of all primary brain tumors in adults. The prognosis for patients with malignant glioma has not changed significantly in recent years. Despite debulking surgery, radiotherapy and cytotoxic chemotherapy, the median survival time is nine to 12 months, an...

Descripción completa

Detalles Bibliográficos
Autor principal: Beauchesne, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712672/
https://www.ncbi.nlm.nih.gov/pubmed/24213227
http://dx.doi.org/10.3390/cancers4010077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712672/
https://www.ncbi.nlm.nih.gov/pubmed/24213227
http://dx.doi.org/10.3390/cancers4010077

Ejemplares similares